tweak-fn14

L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) is a TWEAK-Fn14 signaling cascade inhibitor.

Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody designed to target the TWEAK receptor (TweakR), a protein involved in various cellular responses through its interaction with its natural ligand, TWEAK (Fn14; TNFRSF12A). By directly engaging TweakR signaling and promoting antibody-dependent cell-mediated cytotoxicity (ADCC), enavatuzumab effectively inhibits tumor growth. It also recruits and activates myeloid effector cells to destroy tumor cells. Enavatuzumab has demonstrated the ability to suppress the proliferation of a range of human TweakR-positive cancer cell lines and tumorigenic models both in vitro and in vivo [1] [2].

Aurintricarboxylic acid (NSC-4056) is a strong inhibitor of topoisomerases and other nucleases. It is a potent inhibitor of ribonuclease and topoisomerase II by preventing the binding of the nucleic acid to the enzyme.